Russell Schundler Granted 8,870 RSUs at Liquidia Corp with Vesting Starting in 2028
Russell Schundler, Chief Strategy Officer and General Counsel at Liquidia Corp (NASDAQ: LQDA), was granted 8,870 restricted stock units (RSUs) on November 16, 2026, at no cost. These RSUs will begin vesting on January 11, 2028, with 25% vesting then and the remainder vesting quarterly over the subsequent three years. This grant increases Schundler's direct beneficial ownership to 611,711 shares.
Form 4 Liquidia Corporation: Russell Schundler (Officer) For: 16 November By Investing.com
This article reports on a Form 4 filing for Liquidia Corporation, detailing an insider transaction by Russell Schundler (Officer) on November 16. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. The filing indicates a transaction involving Liquidia Corporation (LQDA) and its officer, Russell Schundler.
Liquidia Corporation (NASDAQ:LQDA) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages
Liquidia Corporation (NASDAQ:LQDA) has received a consensus "Moderate Buy" rating from sell-side brokerages, with an average one-year price target of $75.23. Despite reporting mixed quarterly results, including revenue beating estimates and strong year-over-year growth, the company's EPS missed consensus forecasts. Recent insider selling has been noted, but institutional investors have shown increased interest.
Liquidid Rises as Strong YUTREPIA Growth and a Fresh Analyst Upgrade Boost Sentiment
Liquidia Corporation (LQDA) saw its stock rise by 5.3% due to positive reactions to its third-quarter update and a subsequent analyst upgrade. Investors were particularly encouraged by the rapid sales growth of YUTREPIA, record October shipments, and the resolution of litigation that clears the path for continued commercial expansion. The company reported $222.7 million in YUTREPIA net product sales, a 31% increase from the previous quarter.
Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues
Analysts have significantly upgraded their revenue and earnings per share estimates for Liquidia Corporation (NASDAQ:LQDA) in 2027, expressing a much more bullish outlook on the company's prospects. The consensus now projects revenues of US$895m and a profit of US$2.89 per share, alongside a 12% increase in the price target to US$60.75. This indicates a strong positive shift in analyst sentiment despite a projected slowdown in revenue growth compared to historical rates.
Raymond James upgrades Liquidia stock rating on Yutrepia strength
Raymond James has upgraded Liquidia Technologies (NASDAQ:LQDA) to Strong Buy from Outperform, increasing its price target to $77 from $53. This upgrade is driven by the strong launch performance of Yutrepia for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with product sales reaching $227.7 million in Q3 2026. The firm also noted the removal of a significant legal overhang, contributing to a positive outlook despite anticipated short-term volatility.
BofA raises Liquidia stock price target on strong PAH momentum
BofA Securities has increased its price target for Liquidia Technologies (NASDAQ:LQDA) to $54 from $42, maintaining a Neutral rating, due to strong Pulmonary Arterial Hypertension (PAH) momentum and third-quarter new patient additions. The firm adjusted its Yutrepia PAH estimates and factored in a more gradual runoff for existing PH-ILD patients despite patent deal limitations. Other analysts from Jefferies, BTIG, and Wells Fargo have also raised their price targets for Liquidia, reflecting an optimistic outlook after the company's strong Q3 revenue and the resolution of a patent dispute.
Needham & Company LLC Issues Positive Forecast for Liquidia (NASDAQ:LQDA) Stock Price
Needham & Company LLC raised its price target for Liquidia (NASDAQ:LQDA) from $58.00 to $66.00, maintaining a "buy" rating and suggesting a 28.4% upside. While other analysts have mixed ratings, the consensus is "Hold" with an average target price of $74.92. Liquidia's Q3 revenue surged 314.9% year-over-year to $225.3 million, beating estimates, though the company reported a GAAP loss of $2.64 per share due to a significant charge.
Liquidia Q3 2026 Earnings Call Transcript
Liquidia Corporation reported a 31% increase in third-quarter net product sales of YUTREPIA, reaching $222.7 million, driven by prescriptions for PAH. The company has resolved litigation, allowing it to focus on business operations without requiring existing PH-ILD patients to switch from YUTREPIA. Liquidia plans further studies for YUTREPIA's efficacy and is preparing for new studies in 2027, including a pivotal study for PH-COPD, while reporting a GAAP net loss due to a settlement charge but strong adjusted EBITDA growth.
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Liquidia Corporation announced that its CEO, Dr. Roger Jeffs, and COO/CFO, Michael Kaseta, will present a business update at the 2026 Jefferies Global Healthcare Conference on November 17, 2026. The presentation will cover the company's progress in developing therapies for respiratory and vascular diseases, including its products for pulmonary hypertension. A webcast of the fireside chat will be available on Liquidia's investor relations website.
A Nov. 17 webcast will feature a business update from Liquidia's leaders.
Liquidia Corporation announced that its CEO, Dr. Roger Jeffs, and COO/CFO, Michael Kaseta, will provide a business update at the 2026 Jefferies Global Healthcare Conference on November 17 in London. The presentation will be available via a webcast on Liquidia's investor website, with a replay accessible for at least 30 days. This update comes as Liquidia continues to develop and commercialize products for pulmonary hypertension and other respiratory and vascular diseases.
Form 10-Q Liquidia Corp For: Sep 30
Liquidia Corporation filed its Form 10-Q for the fiscal quarter ended September 30, 2026, reporting a net loss of $236.3 million, largely due to a $389.7 million charge for litigation settlements with United Therapeutics Corporation (UTC) and related parties. The company also disclosed that it will cease promoting YUTREPIA for PH-ILD and amend its label, while continuing to market it for PAH. Future funding requirements will be heavily influenced by YUTREPIA sales and ongoing clinical development of product candidates like L606.
Liquidia 3Q 2026: Revenue $225.3M, EPS ($2.64) — 10-Q Summary
Liquidia reported a significant increase in revenue for Q3 2026, driven by higher YUTREPIA sales, but recorded a net loss primarily due to a substantial litigation settlement charge of $389.7 million. The company's diluted EPS shifted to a loss of ($2.64), and it also saw increased research and development and commercial expenses. Key business highlights include a 331% increase in YUTREPIA product sales and the initiation of a new YUTREPIA study for SSc-RP.
LQDA: Liquidia Corporation filed SEC Form 8-K: Results of...
Liquidia Corporation reported its Q3 2026 financial results, including net product sales of $222.7 million for YUTREPIA, a 31% increase quarter-over-quarter. The company posted a net loss of $236.3 million, primarily due to a $389.7 million charge from its settlement with United Therapeutics, which resolves all outstanding litigation and ensures continued patient care for YUTREPIA. The filing also detailed positive trends like increased Adjusted EBITDA and YUTREPIA's Fast Track designation, alongside negatives such as increased research spending and the anticipated removal of the PH-ILD indication from YUTREPIA's label.
Liquidia Corporation Reports Third Quarter 2026 Financial Results
Liquidia Corporation announced strong financial results for the third quarter of 2026, with YUTREPIA® (treprostinil) inhalation powder sales reaching $222.7 million, a 31% increase from the previous quarter. The company resolved all litigation with United Therapeutics through a global settlement, ensuring continued availability of YUTREPIA, and reported a net loss of $236.3 million due to a $389.7 million litigation charge. Liquidia also highlighted advancements in its clinical pipeline, including Fast Track designation for YUTREPIA in SSc-RP and progress in studies for L606.
Patent Settlement Altering The Investment Case For Liquidia Stock (LQDA)?
Liquidia has settled multiple patent disputes with United Therapeutics regarding its drug YUTREPIA, allowing continued sales for pulmonary arterial hypertension in exchange for defined net payments through April 2027. This resolution shifts the company's focus from legal risks to commercialization and managing cash commitments related to the settlement. Analysts forecast significant revenue and earnings growth for Liquidia by 2029, with some alternate views suggesting higher potential if the PH ILD label removal doesn't significantly impact projections.
Liquidia Corp (NASDAQ:LQDA) Offers Affordable Growth With Strong Revenue and Reasonable Forward Valuation
Liquidia Corp (NASDAQ:LQDA) is identified as an "affordable growth" opportunity due to its strong revenue and earnings growth, supported by solid health and improving profitability. While its trailing P/E is high, forward valuation metrics and expected growth rates suggest a more reasonable price. However, investors should consider risks like the recent profitability being nascent and the deceleration of future growth from past exceptional levels.
A live financial update from Liquidia starts at 8:30 a.m. Nov. 10
Liquidia Corporation (Nasdaq: LQDA) announced it will report its third-quarter 2026 financial results on November 10, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial performance and provide a corporate update, with a rebroadcast available for one year. Liquidia is a biopharmaceutical company focused on developing products for respiratory and vascular diseases using its PRINT® Technology.
Liquidia Corporation (LQDA) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Liquidia Corporation (LQDA), showing the average monthly price return from 2018 to 2026. It also displays the stock's real-time price, recent trading activity, and various market data points. The page indicates that the Canada markets are currently closed.
Liquidia (NASDAQ:LQDA) Insider Sells 688 Shares of Company Stock
Liquidia (NASDAQ:LQDA) insider Jason Adair sold 688 shares of company stock for $29,714.72 to cover tax withholding obligations from vested equity awards, retaining 177,269 shares. The company's shares rose 0.6% to $45.72, and while revenue significantly increased year-over-year, earnings per share of $0.74 slightly missed analyst expectations. Liquidia currently holds a consensus "Hold" rating from analysts with an average price target of $72.85, and institutional investors own about 64.54% of the stock.
To cover stock-award taxes, Liquidia (LQDA) accounting chief sells 1,581 shares.
Dana Boyle, Chief Accounting Officer at Liquidia Corp (LQDA), sold 1,581 shares of common stock on October 26, 2026, at $43.19 per share. This transaction was conducted under a Rule 10b5-1 plan adopted in December 2023 and was primarily to cover taxes associated with the settlement of restricted stock units. Following this sale, Boyle reported holding 164,028 shares.
Liquidia (LQDA) Jumps 5.7% to $45.06
Liquidia Corporation (LQDA) saw its shares jump 5.7% to $45.06 on Monday, with a volume of 2.3M shares. The surge was noted in a Benzinga roundup of rising stocks, but no specific company-level catalyst, such as clinical trial results or financial updates, was publicly disclosed. This suggests the rally might be due to broader sector momentum or technical trading patterns rather than fundamental news specific to Liquidia.
Liquidia Corporation Estimates – XETR:LT4
The article provides an overview of Liquidia Corporation's financial estimates, listed under the ticker XETR:LT4 on the Deutsche Borse Xetra. It highlights the availability of reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics for both annual and quarterly periods. Users can compare actual results with average, high, and low estimates, and visualize trends over time.
Liquidia Corporation (LQDA) Stock forecasts
Argus has issued a "HOLD" investment rating for Liquidia Corp (LQDA) and raised its target price to $35.00. The report details subratings for industry, management, safety, financial strength, growth, and value, all of which are categorized as either "Medium" or "Low." The current stock price is $42.65.
United Therapeutics Faces A Lower Tyvaso Ceiling After Liquidia Deal
United Therapeutics is facing a lower near-term revenue ceiling for its lung drug Tyvaso after settling a dispute with Liquidia, leading RBC Capital Markets to trim its forecasts and price target. The settlement shifts focus from legal drama to market competition, with uncertainty surrounding how quickly patients will transition to Liquidia's rival drug, Yutrepia. While RBC lowered its price target and near-term revenue expectations, it raised its 2027 estimate, arguing that the deal allows United Therapeutics to focus on its planned idiopathic pulmonary fibrosis launch in April 2027.
United Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC Says
RBC believes United Therapeutics (UTHR) will experience limited near-term upside for its drug Tyvaso due to a recent settlement with Liquidia (LQDA). The article notes that premium subscription is required to read the full report.
Arquitos Capital: Liquidia Buyout & Income SPV
Arquitos Capital has launched a Liquidia Buyout and Income SPV, a co-investment vehicle, following the resolution of patent litigation and strong commercial execution of Yutrepia. The SPV will use a 50/50 capital allocation model, combining long-dated calls for upside potential upon a buyout or equity re-rating, and a volatility-harvesting overlay to generate quarterly cash distributions and cushion downside. This strategy aims to capitalize on Liquidia's current valuation, which Arquitos believes makes it an attractive acquisition target.
Las ETF que invierten en acciones de Liquidia Corporation
This article lists various Exchange Traded Funds (ETFs) that hold shares of Liquidia Corporation (LT4). The list, sorted by market value, provides details such as issuer, management style, expense ratio, assets under management (AUM), price, and total return, offering investors insights into opportunities with lower risk. These ETFs primarily focus on small-cap, growth, and healthcare sectors.
Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy
Liquidia Corporation (NASDAQ:LQDA) saw its stock price surge by 6.3% to $36.27 on Tuesday after four Wall Street firms raised their price targets, indicating increased confidence in the company's future. The average new price target reached $57, suggesting significant potential upside. This bullish sentiment reflects optimism around Liquidia's commercial execution and pipeline, with analysts believing the current valuation undervalues its growth trajectory.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Liquidia Corp
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Liquidia Corporation (NASDAQ:LQDA) following an adverse patent litigation ruling on October 5, 2026, which led to a 57% stock price drop. The ruling found two patent claims valid and infringed, raising concerns about Yutrepia's availability and its PH-ILD indication, despite Liquidia previously stating litigation posed no material risk. The firm is encouraging investors who purchased Liquidia securities to join their investigation.
StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics
Liquidia's shares surged after settling six lawsuits with United Therapeutics, which had caused a significant plunge in its stock previously. The settlement includes Liquidia paying United Therapeutics $380.7 million, removing a PH-ILD indication from Yutrepia's label, and allows Liquidia to continue selling Yutrepia for PAH and developing other treprostinil formulations. Analysts are divided on which company benefited more from the settlement, with some seeing it as a win for Liquidia due to the removal of legal overhangs and others viewing it as a clear win for United Therapeutics for protecting its PH-ILD franchise and gaining significant sales from patient transitions.
Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients
Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending lawsuits between the companies. The agreement ensures that YUTREPIA (treprostinil) inhalation powder remains available for patients with pulmonary arterial hypertension (PAH) and allows Liquidia to focus on growing the brand. Liquidia will pay a total of $380.7 million across 2026 and 2027 as part of the settlement.
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
This Stocktwits Wall Street Wrap highlights upgrades for Crocs (CROX) and Liquidia (LQDA) due to growth potential and resolved legal issues, respectively. Conversely, Albertsons (ACI) faced downgrades amid operational concerns, while AST SpaceMobile (ASTS) and AT&T (T) were pressured by growing competition from SpaceX. The article details the reasons behind these analyst actions and the performance of the mentioned stocks year-to-date.
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
This week, Crocs (CROX) and Liquidia (LQDA) saw their stocks upgraded due to growth potential and resolved legal issues, respectively. In contrast, Albertsons (ACI) faced multiple downgrades due to business challenges and financial outlook concerns. Additionally, AT&T (T) and AST SpaceMobile (ASTS) were downgraded amid increasing competition from SpaceX in broadband and satellite-based phone services.
Liquidia Corporation Stock 12‑Month Price Target Raised to $53.5, Implies 100% Upside
Liquidia Corporation (LQDA) has seen its average price target raised from $53 to $53.5 by 8 analysts, with forecasts ranging from $33 to $70 per share. This updated target implies an approximately 100% potential upside based on the Oct. 13 closing price. The consensus rating among 9 covering analysts remains "Buy," with 6 Buys, 3 Holds, and 0 Sells.
How Much Downside Is Left In Liquidia Stock?
Shares of Liquidia (LQDA) recently dropped significantly after a federal judge ruled that its drug Yutrepia infringed on a United Therapeutics patent, despite a subsequent settlement. The article analyzes Liquidia's past market downturns and recovery times, noting its current strong operating margin and cash position. It also highlights potential future cost increases and provides investment strategies for LQDA.
Liquidia Corp chief development officer sells $31,356 in stock
Liquidia Corp's Chief Development Officer, Sanjeev Khindri, sold 1,101 shares for $31,356 to cover taxes from restricted stock units. This transaction occurred under a Rule 10b5-1 trading plan. The sale comes amidst recent negative analyst adjustments and price target reductions for Liquidia due to an unfavorable patent ruling.
Liquidia (NASDAQ:LQDA) Upgraded to "Outperform" at Lifesci Capital
Liquidia (NASDAQ:LQDA) was upgraded from a "market perform" to an "outperform" rating by Lifesci Capital, with a price target of $59, suggesting a 73.84% upside. This upgrade follows a significant 26.6% increase in Liquidia's stock price to $33.94. The company recently reported strong revenue growth but slightly missed earnings estimates, while institutional investors hold a majority stake and insiders have been selling shares.
Liquidia soars 27% after settlement resolves litigation (LQDA:NASDAQ)
Liquidia Corporation's stock jumped nearly 27% following the announcement of a global settlement with United Therapeutics, resolving all pending litigation. This settlement removes a significant cloud of legal uncertainty, which had previously impacted the stock. While opportunities for YUTREPIA's commercialization are enhanced, some risks remain regarding product adoption and the full impact of settlement terms on growth and valuation.
United Therapeutics secures $381M settlement in patent dispute with competitor
United Therapeutics has secured a $381 million settlement in a patent dispute with Liquidia, resolving a conflict that originated in 2020. The dispute centered on competing treatments for pulmonary arterial hypertension. Martine Rothblatt is the chair and CEO of United Therapeutics.
Liquidia Announces Global Settlement Resolving All Pending
Liquidia Corporation announced a global settlement with United Therapeutics Corporation, resolving all pending litigation and ensuring the continued availability of YUTREPIA for patients with pulmonary arterial hypertension (PAH). Liquidia will pay United Therapeutics a net of $380.7 million in installments, funded by strong YUTREPIA sales and existing cash reserves. The settlement allows Liquidia to focus on growing the YUTREPIA brand, advancing L606 clinical programs, and exploring new treatments, while removing the PH-ILD indication from YUTREPIA's label.
Liquidia Corporation Stock 12‑Month Price Target Raised to $52.71, Implies 97% Upside
Liquidia Corporation's average 12-month price target has increased to $52.71 from $52.14, according to estimates from seven analysts. This new target implies a potential upside of approximately 97% based on the Oct. 13 closing price. The consensus rating for Liquidia Corporation remains a "Buy" among nine analysts.
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
Liquidia's stock surged 42% after settling all pending lawsuits with United Therapeutics for $380.7 million. This settlement, which consumes 96% of Liquidia's cash and removes a key indication (PH-ILD) from its drug YUTREPIA, was seen as a relief by investors who feared a complete market withdrawal of the drug following a September patent ruling. Despite the stock jump, Liquidia still trades significantly below its pre-ruling price, with most of its cash committed to legal payments.
Liquidia Shares Surge 42.48% After Hours - United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA)
Liquidia Corporation shares surged over 42% after hours following a global settlement with United Therapeutics Corporation. The agreement resolves all pending litigation, stemming from a patent infringement ruling that required Liquidia to remove the PH-ILD indication from its YUTREPIA label. Liquidia will make several payments totaling hundreds of millions to United Therapeutics, which it plans to fund through YUTREPIA sales and existing cash reserves.
Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battle (LQDA:NASDAQ)
Liquidia shares surged 42% following a $380.7 million settlement with United Therapeutics. This agreement resolves six outstanding lawsuits and ensures Liquidia's continued ability to commercialize YUTREPIA for pulmonary arterial hypertension. The settlement involves an initial payment of $175 million, followed by two installments of $72.7 million.
Liquidia Just Paid $380 Million to End a Patent War That Crushed the Stock
NULL
Liquidia (NASDAQ:LQDA) Insider Sells 9,218 Shares of Company Stock
Liquidia insider Rajeev Saggar sold 9,218 shares of company stock for approximately $262,529 to cover tax obligations from vested equity awards, reducing his stake by 6.8%. This sale follows earlier, larger sales in August. The company recently settled litigation with United Therapeutics, which allows continued commercialization of YUTREPIA but requires a $380.7 million payment and the removal of a key indication from the product's label, impacting cash flow and market potential.
Liquidia Corp CEO Roger Jeffs sells $932,549 in stock
Liquidia Corp CEO Roger Jeffs sold 32,744 shares of the company's common stock for $932,549 on October 12, 2026, to cover taxes from restricted stock unit settlements. Concurrently, he acquired 28,166 shares through the conversion of performance stock units. Following these transactions, Jeffs directly and indirectly holds over 2.2 million shares, while the company faces legal challenges related to patent litigation.
A tax-related sale at Liquidia (LQDA) totals 1,101 shares at $28.48 each.
Sanjeev Khindri, Chief Development Officer at Liquidia Corp (LQDA), sold 1,101 common shares at $28.48 each on October 12, 2026. This transaction was executed under a Rule 10b5-1 plan adopted in March 2026 and was specifically to cover taxes associated with the settlement of previously granted restricted stock units. Following the sale, Khindri's direct holdings in common stock amounted to 64,846 shares.
Liquidia Corporation and United Therapeutics Reach Global Settlement Resolving All Pending Litigation
Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six ongoing lawsuits between the companies. The agreement ensures continued patient access to YUTREPIA® for pulmonary arterial hypertension (PAH) and involves Liquidia paying United Therapeutics a net total of $380.7 million in installments over 2026 and 2027. Despite the payment obligations, Liquidia reports strong preliminary Q3 2026 YUTREPIA sales of $222.7 million and a cash position of $396.1 million, enabling them to fund the settlement and continue advancing clinical programs.